An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the coronavirus at the root of COVID-19.

Researchers found an antibody that protects against a wide range of potentially lethal influenza viruses, advancing efforts to design of a universal vaccine.

Preparing a seasonal flu vaccine with the G186V mutation may prevent a vexing problem that commonly occurs during the vaccine manufacturing process.

The International AIDS Vaccine Initiative (IAVI) announced the start of a Phase I clinical trial to test a novel HIV vaccine candidate, an advance in vaccine design enabled by Scripps Research discoveries.